Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis - 2A Gastronomic Experience in Healthy Enjoyments: A Survey of \Nutritious and Tasty\ Solid Cooking Recipe Book
- 3Hitting the brakes: Hubble Space Telescope watches doomed comet reverse its spin
- 4Best Internet based Course for Learning Another Dialect: Which Stage Do You Like?
- 521 Things You Ought to Never Share with Your Childless Companion
- The Best Web-based Courses for Expertise Improvement
- Osteoporosis, the silent disease, can shorten your life − here’s how to prevent fractures and keep bones healthy
- One lightly wounded after Iranian missile barrage targets northern Israel
- Pick Your Favored kind of sandwich
- Displaced Palestinian families suffer as heavy rains flood Gaza tent camps
- Triumph's 400 Range Has Just Changed In India, And Here's Why
- Judge approves Purdue Pharma’s new $7B opioid settlement with the Sacklers
- German economic institutes cut forecast in half over Iran war
- Share your pick for the tree that you love for its novel magnificence!
